Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EPS (Basic): 2016-2024

Historic EPS (Basic) for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to -$4.34.

  • Rhythm Pharmaceuticals' EPS (Basic) fell 12.33% to -$0.82 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.10, marking a year-over-year increase of 28.41%. This contributed to the annual value of -$4.34 for FY2024, which is 35.62% down from last year.
  • As of FY2024, Rhythm Pharmaceuticals' EPS (Basic) stood at -$4.34, which was down 35.62% from -$3.20 recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' EPS (Basic) ranged from a high of -$1.40 in FY2021 and a low of -$4.34 during FY2024.
  • For the 3-year period, Rhythm Pharmaceuticals' EPS (Basic) averaged around -$3.67, with its median value being -$3.47 (2022).
  • In the last 5 years, Rhythm Pharmaceuticals' EPS (Basic) crashed by 147.86% in 2022 and then increased by 7.78% in 2023.
  • Yearly analysis of 4 years shows Rhythm Pharmaceuticals' EPS (Basic) stood at -$1.40 in 2021, then crashed by 147.86% to -$3.47 in 2022, then grew by 7.78% to -$3.20 in 2023, then crashed by 35.62% to -$4.34 in 2024.